SCHEMBL298568

SCHEMBL298568

COc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccnc4)c3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
KEAP1 Q14145 1/20 0.48
NFE2L2 Q16236 1/20 0.48
CYP3A4 P08684 2/20 0.47
PIK3CA P42336 3/20 0.45
TCF4 P15884 1/20 0.45
CTNNB1 P35222 1/20 0.45
BRD4 O60885 1/20 0.44
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
AURKA O14965 1/20 0.43
BTK Q06187 1/20 0.43
AAK1 Q2M2I8 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SLC40A1 Q9NP59 1/20 0.43
CYP17A1 P05093 1/20 0.42
NTRK1 P04629 1/20 0.42
KIT P10721 1/20 0.42
NEK1 Q96PY6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298357 0.88 CYP3A4 (0.52) GAACYP3A4PIK3CABRD4BTK
SCHEMBL297350 0.86 CYP3A4 (0.51) GAACYP3A4PIK3CABRD4AURKA
SCHEMBL299508 0.86 CYP3A4 (0.53) CYP3A4PIK3CABRD4BTKKMT2A
SCHEMBL298808 0.86 CYP3A4 (0.49) CYP3A4PIK3CABRD4BTKKMT2A
SCHEMBL298592 0.84 CAMKK2 (0.52) CYP3A4PIK3CABRD4AAK1NTRK1
SCHEMBL298660 0.84 PIK3CA (0.57) CYP3A4PIK3CABRD4AAK1NTRK1
SCHEMBL299448 0.83 PIK3CA (0.52) CYP3A4PIK3CABRD4AURKABTK
SCHEMBL298351 0.82 PIK3CA (0.49) CYP3A4PIK3CABRD4BTKAAK1
SCHEMBL297235 0.80 AAK1 (0.44) BRD4BTKAAK1SMN1; SMN2NTRK1
SCHEMBL299341 0.79 AAK1 (0.43) BTKAAK1SMN1; SMN2NTRK1NEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF GAA 3697/4885KEAP1 2566/4885NFE2L2 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.